Focus: Arvinas is a biotechnology company specializing in bifunctional small molecules for protein degradation, with a focused pipeline in oncology. The company is based in New Haven, CT and operates at the mid-cap biotech stage with 8 active job openings.
Profile data last refreshed 33m ago · AI intelligence enriched 2mo ago
Stable — net -1 jobs in 30d
1 added, 2 removed. Backfill posture.
Best fit for scientists and operators seeking deep involvement in a cutting-edge platform technology at inflection point, but not for those prioritizing rapid career progression or company scale.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Arvinas
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Arvinas's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
+2 more
+2 more
Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer - Yahoo Finance
Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer Yahoo Finance
New Haven biotech Arvinas signs potential $405M drug licensing deal - Hartford Business Journal
New Haven biotech Arvinas signs potential $405M drug licensing deal Hartford Business Journal
Rigel Pharmaceuticals Enters an Exclusive Global Licensing Agreement with Arvinas and Pfizer for Veppanu | PharmExec - Pharmaceutical Executive
Rigel Pharmaceuticals Enters an Exclusive Global Licensing Agreement with Arvinas and Pfizer for Veppanu | PharmExec Pharmaceutical Executive
Arvinas, Pfizer Partner With Rigel Pharmaceuticals on Global VEPPANU Commercialization - Moomoo
Arvinas, Pfizer Partner With Rigel Pharmaceuticals on Global VEPPANU Commercialization Moomoo
Arvinas, Pfizer find new partner for ‘Protac’ breast cancer drug - BioPharma Dive
Arvinas, Pfizer find new partner for ‘Protac’ breast cancer drug BioPharma Dive
Why Is Rigel Pharmaceuticals - Arvinas (NASDAQ:ARVN), Pfizer (NYSE:PFE), Rigel Pharmaceuticals (NASDAQ:RI - Benzinga
Why Is Rigel Pharmaceuticals - Arvinas (NASDAQ:ARVN), Pfizer (NYSE:PFE), Rigel Pharmaceuticals (NASDAQ:RI Benzinga
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo